Product details
Background:Ixekizumab is a humanized monoclonal antibody to interleukin-17A which acts as an antiinflammatory agent and is used to treat moderate-to-severe plaque psoriasis. Ixekizumab has not been linked to serum enzyme elevations during therapy or to instances of idiosyncratic acute liver injury.
• The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond., PMID:30127781
• Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability., PMID:26431948
• IL-17A functions and the therapeutic use of IL-17A and IL-17RA targeted antibodies for cancer treatment., PMID:37579542
• The role of IL-17 and anti-IL-17 agents in the immunopathogenesis and management of autoimmune and inflammatory diseases., PMID:34863654
• IL-17 for therapy., PMID:28633806
• Association Between., PMID:35271496
• Vunakizumab: First Approval., PMID:39497021
• The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies., PMID:31278139
• IL-17A Modulates Peritoneal Macrophage Recruitment and M2 Polarization in Endometriosis., PMID:32117261
• Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F., PMID:32973785






